ISRCTN22433402CompletedPhase 4
Efficacy and safety of fesoterodine fumarate in neurogenic detrusor overactivity due to spinal cord lesion (SCL) or multiple sclerosis (MS)
ational Rehabilitation Center0 sites85 target enrollmentStarted: June 2, 2016Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- Enrollment
- 85
Study Overview
Brief Summary
2021 Results article in https://doi.org/10.1002/nau.24790 (added 02/03/2022)
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •1. Aged between 18-80 years old
- •2. Suffering from neurogenic detrusor overactivity, confirmed by urodynamics testing, secondary to MS or SCI of at least 6 months prior to enrollment
- •3. Patients suffering from MS should be clinically stable for at least 3 months prior to enrollment
Exclusion Criteria
- •2. History of urothelial cancer
- •3. Urolithiasis
- •4. Stress incontinence
- •5. Interstitial cystitis
- •6. Pelvic organ prolapsed (= III grade)
- •7. Prior pelvic surgery or pelvic radiation treatment
- •8. Uncontrolled narrow angle glaucoma
- •9. Pregnancy
- •10. Dementia
Investigators
Similar Trials
Completed
Not Applicable
rodynamic efficacy of fesoterodine for the treatment of neurogenic detrusor overactivity and/or low-compliance bladderneurogenic bladderJPRN-UMIN000037584Dokkyo Medical University77
Completed
Phase 3
Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.Overactive BladderNCT00611026Pfizer2,417
Not yet recruiting
Not Applicable
Objective assessment of fesoterodine for overactive bladder with benign prostatic hyperplasiaOveractive bladder associated with benign prostatic hyperplasiaJPRN-UMIN000010296Dept. of Urology, Kyoto University Graduate School of Medicine40
Completed
Phase 3
Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)Overactive BladderNCT00444925Pfizer1,712
Completed
Phase 2
Evaluation Of The Ability Of Fesoterodine To Increase Urethral Pressure In Stress Urinary Incontinence PatientsStress Urinary IncontinenceNCT01042236Pfizer22